GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Karyopharm Therapeutics Inc (STU:25K) » Definitions » Pretax Margin %

Karyopharm Therapeutics (STU:25K) Pretax Margin % : -82.63% (As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Karyopharm Therapeutics Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Karyopharm Therapeutics's Pre-Tax Income for the three months ended in Sep. 2024 was €-28.9 Mil. Karyopharm Therapeutics's Revenue for the three months ended in Sep. 2024 was €34.9 Mil. Therefore, Karyopharm Therapeutics's pretax margin for the quarter that ended in Sep. 2024 was -82.63%.

The historical rank and industry rank for Karyopharm Therapeutics's Pretax Margin % or its related term are showing as below:

STU:25K' s Pretax Margin % Range Over the Past 10 Years
Min: -71063.64   Med: -538   Max: -58.73
Current: -58.73


STU:25K's Pretax Margin % is ranked better than
60.22% of 1013 companies
in the Biotechnology industry
Industry Median: -148.6 vs STU:25K: -58.73

Karyopharm Therapeutics Pretax Margin % Historical Data

The historical data trend for Karyopharm Therapeutics's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Karyopharm Therapeutics Pretax Margin % Chart

Karyopharm Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Pretax Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -487.98 -181.30 -59.01 -105.00 -97.77

Karyopharm Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -95.79 -123.59 -112.57 55.76 -82.63

Competitive Comparison of Karyopharm Therapeutics's Pretax Margin %

For the Biotechnology subindustry, Karyopharm Therapeutics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Karyopharm Therapeutics's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Karyopharm Therapeutics's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Karyopharm Therapeutics's Pretax Margin % falls into.



Karyopharm Therapeutics Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Karyopharm Therapeutics's Pretax Margin for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-130.926/133.912
=-97.77 %

Karyopharm Therapeutics's Pretax Margin for the quarter that ended in Sep. 2024 is calculated as

Pretax Margin=Pre-Tax Income (Q: Sep. 2024 )/Revenue (Q: Sep. 2024 )
=-28.872/34.943
=-82.63 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Karyopharm Therapeutics  (STU:25K) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Karyopharm Therapeutics Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Karyopharm Therapeutics's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Karyopharm Therapeutics Business Description

Traded in Other Exchanges
Address
85 Wells Avenue, 2nd Floor, Newton, MA, USA, 02459
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Karyopharm Therapeutics Headlines

No Headlines